HERTFORDSHIRE, England and
PITTSBURGH, Feb. 16, 2016 /PRNewswire/ -- Mylan N.V.
(NASDAQ, TASE: MYL) today announced that it filed its Annual Report
on Form 10-K for the year ended December 31,
2015 with the U.S. Securities and Exchange Commission on
Feb. 16, 2016. The Annual Report is
available through the Investors section of the company's website at
www.mylan.com/investors. In addition, the company's
shareholders may receive a hard copy of the Annual Report, free of
charge, upon request by contacting Mylan Investor Relations at
724.514.1813 or investor.relations@mylan.com.
Mylan is a global pharmaceutical company committed to setting
new standards in healthcare. Working together around the world to
provide 7 billion people access to high quality medicine, we
innovate to satisfy unmet needs; make reliability and service
excellence a habit; do what's right, not what's easy; and impact
the future through passionate global leadership. We offer a growing
portfolio of more than 1,400 generic and branded pharmaceuticals,
including antiretroviral therapies on which nearly 50% of people
being treated for HIV/AIDS in the developing world depend. We
market our products in approximately 165 countries and territories.
Our global R&D and manufacturing platform includes more than 50
facilities, and we are one of the world's largest producers of
active pharmaceutical ingredients. Every member of our nearly
35,000-strong workforce is dedicated to creating better health for
a better world, one person at a time. Learn more at mylan.com.
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/mylan-files-annual-report-on-form-10-k-for-year-ended-dec-31-2015-300220524.html
SOURCE Mylan N.V.